Current Report Filing (8-k)
30 January 2014 - 10:03PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 29, 2014
Idenix Pharmaceuticals, Inc.
(Exact Name of Registrant as Specified in Charter)
|
|
|
|
|
Delaware |
|
000-49839 |
|
45-0478605 |
(State or Other Juris- diction of Incorporation |
|
(Commission File Number) |
|
(IRS Employer Identification No.) |
|
|
320 Bent Street
Cambridge, MA |
|
02141 |
(Address of Principal Executive Offices) |
|
(Zip Code) |
Registrants telephone number, including area code: 617-995-9800
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any
of the following provisions (see General Instruction A.2. below):
|
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 8.01. Other Events
On January 29, 2014, Idenix Pharmaceuticals, Inc. (the Company or Idenix) announced that the United States Patent
and Trademark Office Patent Trial and Appeal Board (USPTO) issued a decision in the first patent interference proceeding (No. 105,871) concerning one of the Companys patent applications (U.S. Patent Application 12/131,868) and an issued patent
(U.S. Patent 7,429,572) owned by Gilead Pharmasset LLC (Gilead) that covers certain 2-methyl- 2-fluoro nucleoside compounds useful in the treatment of the hepatitis C virus (HCV). The USPTO determined that Idenix is not
entitled to priority of invention and judgment was entered in favor of Gilead.
Idenix does not believe that the patent application at
issue in the interference is relevant to any of the compounds currently under clinical development, including samatasvir, its NS5A inhibitor which is in two ongoing 12-week phase II all-oral HCV combination studies, or IDX21437, its lead uridine
nucleotide prodrug which is in an ongoing phase I/II clinical trial.
The full text of the press release is attached hereto as Exhibit
99.1.
Item 9.01. Financial Statements and Exhibits
|
|
|
99.1 |
|
Press Release dated January 29, 2014 |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
Idenix Pharmaceuticals, Inc. |
|
|
|
|
Date: January 29, 2014 |
|
|
|
By: |
|
/s/ Maria Stahl |
|
|
|
|
|
|
Maria Stahl Senior Vice President and
General Counsel |
EXHIBIT INDEX
|
|
|
Exhibit No. |
|
Description |
|
|
99.1 |
|
Press release dated January 29, 2014 |
(MM) (NASDAQ:IDIX)
Historical Stock Chart
From Sep 2024 to Oct 2024
(MM) (NASDAQ:IDIX)
Historical Stock Chart
From Oct 2023 to Oct 2024